Stryker (NYSE:SYK) recently received FDA clearance for its Incompass® Total Ankle System, a significant product innovation that highlights the company's commitment to advancing patient care. Over the ...

The star of Monday’s deal is gusacitinib, a small-molecule drug that Formation is developing for chronic hand eczema. Sanofi ...

Having secured one of last year’s largest funding rounds, AI-focused Formation Bio is now eyeing up 545 million euros ($626 ...

Below is Validea's guru fundamental report for STRYKER CORP (SYK). Of the 22 guru strategies we follow, SYK rates highest using our Multi-Factor Investor model based on the published strategy of ...

Investors in Stryker Corp (Symbol: SYK) saw new options become available today, for the August 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SYK ...

This has positioned BSX as the second-largest player globally, largely due to the rapid adoption of pulsed field ablation ...

Gross margins declined to 66.4% in the first quarter from 67.6% a year ago due to increased depreciation, a higher mix of ...

Stryker (NYSE:SYK) announced today that it received FDA 510(k) clearance for its Incompass total ankle system.

Buying $1000 In SYK: If an investor had bought $1000 of SYK stock 10 years ago, it would be worth $3,978.93 today based on a price of $378.63 for SYK at the time of writing.